Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan
Open Access
- 3 April 2020
- journal article
- research article
- Published by Elsevier BV in Journal of Microbiology, Immunology and Infection
- Vol. 53 (3), 488-492
- https://doi.org/10.1016/j.jmii.2020.03.032
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trialTrials, 2018
- Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeysNature, 2016
- Coronaviruses — drug discovery and therapeutic optionsNature Reviews Drug Discovery, 2016
- Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common MarmosetThe Journal of Infectious Diseases, 2015
- Mesenchymal Stromal Cells: Sensors and Switchers of InflammationCell Stem Cell, 2013
- Treatment and vaccines for severe acute respiratory syndromeThe Lancet Infectious Diseases, 2005
- Treatment and vaccines for severe acute respiratory syndromeThe Lancet Infectious Diseases, 2005
- Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findingsThorax, 2004
- Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study.2003
- Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirusNature, 2003